CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|January 16, 2025
- MHE January 2025
- Volume 35
- Issue 1
Cybersecurity on Health Plan Radar | Predictions for 2025
Author(s)George Pappas
A prediction for 2025 by George Pappas, CEO of Intraprise Health.
Advertisement
Health plans in 2025 will pay more attention to cybersecurity. While the majority of hacks and breaches target healthcare systems and vendors, insurers also have valuable information that hackers want.
Plans are taking steps to protect themselves and their data. For example, the Blue Cross Blue Shield Association will require all its locals to perform a National Institute of Standards and Technology audit in 2025. Other insurers will follow suit. Their reputations are at stake.
Articles in this issue
over 1 year ago
Lab Power | Predictions for 2025over 1 year ago
Here we are Now, Enable us | Predictions for 2025over 1 year ago
Simulacra of Data as an Answer | Predictions for 2025over 1 year ago
AI Soups up Payer Operations | Predictions for 2025over 1 year ago
Digital Lifeline | Predictions for 2025over 1 year ago
Show us Your Prices | Predictions for 2025Advertisement
Related to this article
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
One of teledentistry's most valuable applications is triage — helping a patient understand whether a concern can wait for an appointment, requires prompt attention or warrants emergency medical care.
Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.
In both mice and human cells, a small molecule selectively blocked the activity of MAP4K4, a protein involved in several major biological pathways.
Steering claims away from 340B-eligible pharmacies is one option but also the most disruptive, said Jeff Dunn, Pharm.D., MBA, of NeosRx.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Why consumers still can’t comparison shop for medication
2
Teledentistry is a step in closing the gap in dental care
3
Low birth volume, finances tied to hospital obstetric unit closures
4
Jeff Dunn, Pharm.D., MBA, on 340B rebates vs. discounts — and transparency | PBMI 2026
5